Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?

Sanofi’s dengue vaccine Dengvaxia’s checkered growth trajectory may be under further strain, with an expert group of the World Health Organization recommending a “pre-vaccination screening strategy” as the “preferred option” in countries evaluating vaccination as part of their dengue control program.

Only dengue-seropositive persons should be vaccinated under this plan, the Strategic Advisory Group of Experts (SAGE) on Immunization, the principal advisory group to WHO for vaccines and immunization, said as part of its recent updated recommendations on Dengvaxia